araag2/HINT huggingface dataset:
Clinical trial NCT00724126 (phase 3, status: completed)
Conditions: non-constipation irritable bowel syndrome
ICD codes: K58.2, K58.8, K58.0, K58.1, K58.9
Drugs: rifaximin, placebo
SMILES: [H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed IBS diagnosis per Rome II criteria for diagnosis of IBS.

          -  Colonoscopy within 2 years as part of IBS diagnostic evaluation.

          -  Has active symptoms of non-constipation IBS at baseline as measured by average daily
             scores for abdominal pain/discomfort, bloating, and stool consistency.

        Exclusion Criteria:

          -  Symptoms of constipation.

          -  History of other gastrointestinal diseases.

          -  Type 1 or 2 diabetes.

          -  Lactose intolerance not controlled by lactose-free diet.
Clinical trial NCT01857622 (phase 3, status: completed)
Conditions: non-valvular atrial fibrillation
ICD codes: I49.01, I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: du-176b 15mg, du-176b 30mg, du-176b 60mg
SMILES: CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with NVAF and SRI, or patients with NVAF and Normal/MiRI.

        Exclusion Criteria:

          -  Patients who are on hemodialysis or patients who may start hemodialysis before the
             follow-up assessment

          -  Patients who are at a significantly high risk for bleeding

          -  Patients who are receiving treatment with any anticoagulant drugs excluding warfarin,
             rivaroxaban, and dabigatran

          -  Patients who have evidence of hepatic function test abnormalities
Clinical trial NCT00604539 (phase 3, status: completed)
Conditions: synovitis, osteoarthritis, joint diseases, muskuloskeletal diseases
ICD codes: M65.9, M67.30, M67.311, M67.312, M67.319, M67.321, M67.322, M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019, M01.X0, M01.X9
Drugs: chondroitin sulphate (condrosan), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Primary OA of the knee according to ACR with synovitis criteria (warmth, swelling or
             effusion);

          -  OA of radiological stages 2 and 3 according to Kellgren-Lawrence;

          -  Minimum joint space width ≥2 mm in the medial femorotibial compartment on standing
             knee X-ray;

          -  VAS of pain while walking ≥40 mm.

        Exclusion Criteria:

          -  Known allergy to chondroitin sulphate;

          -  Progressive or serious pathologies (cancer, AIDS,...);

          -  Other bone and articular diseases (antecedents and/or current signs) such as
             chondrocalcinosis, Paget's disease, rheumatoid arthritis, aseptic osteonecrosis, gout,
             septic arthritis, ochronosis, acromegaly, hemochromatosis, Wilson's disease,
             osteochondromatosis;

          -  Corticosteroids (oral, injectable), indomethacin, therapeutic dose of glucosamine or
             chondroitin sulphate during the 12 weeks preceding inclusion;

          -  Hyaluronic Acid (intra-articular pathway) during the 26 weeks preceding inclusion;

          -  Radioactive synovectomy during the 12 weeks preceding inclusion;

          -  If the patient is receiving NSAID at baseline (D0), it should be maintained at a
             stable dosage as much as possible from D0 to D180. In the open phase of the study
             (D180 to D360), NSAID will also be allowed as rescue medication along with
             acetaminophen.
Clinical trial NCT00415597 (phase 3, status: completed)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: alo-01 (morphine sulfate plus naltrexone hydrochloride er)
SMILES: [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject 18-70 years of age

          -  Subject agrees to refrain from taking any opioid medications other than study
             medication during study period.

          -  History of chronic moderate to severe pain caused by a nonmalignant condition for at
             least 3 months prior to baseline

        Exclusion Criteria:

          -  Subject has a documented history of allergic reaction or clinically significant
             intolerance to morphine or other opioids, such that treatment with morphine is
             contraindicated.

          -  Subject is pregnant or breast-feeding.

          -  Subject is receiving chemotherapy, or has an active malignancy of any type or has been
             diagnosed with cancer within the past three years (excluding squamous or basal cell
             carcinoma of the skin).

          -  Subject has a documented history of drug abuse/dependence/misuse or narcotic analgesic
             abuse/dependence/misuse within five years prior to the Baseline Visit.

          -  Subject has a Body Mass Index (BMI)>45kg/m2.
Clinical trial NCT00435409 (phase 3, status: completed)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: sunitinib + capecitabine, capecitabine
SMILES: CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Locally advanced or metastatic disease that can be measured. Patients with bone-only
             disease are also allowed to enter the study.

          -  Previous treatment with an anthracycline and a taxane in any setting

          -  Progression on first or second line regimen or adjuvant regimen if disease free
             interval less than 12 months

        Exclusion Criteria:

          -  History of inflammatory carcinoma if there is no other measurable disease

          -  More than 2 chemotherapy agents in the advanced disease setting

          -  Brain metastases
Clinical trial NCT00571649 (phase 3, status: completed)
Conditions: venous thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: rivaroxaban (xarelto, bay59-7939), enoxaparin, rivaroxaban placebo, enoxaparin placebo
SMILES: ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients aged 40 years or more

          -  Patients at risk of venous thromboembolic events being hospitalized for acute medical
             conditions as follows:

               -  Heart failure, New York Heart Association (NYHA) class III or IV

               -  Active cancer

               -  Acute ischemic stroke

               -  Acute infectious and inflammatory diseases, including acute rheumatic diseases

               -  Acute respiratory insufficiency

               -  Additional risk factor for VTE, including reduced mobility

        Exclusion Criteria:

          -  Conditions that contraindicate the use of antithrombotic therapy with the Low
             Molecular-Weight Heparin (LMWH) enoxaparin

          -  Conditions that may increase the risk of bleeding, including intracranial hemorrhage

          -  Required drugs or procedures which may interfere with the study treatment

          -  Concomitant conditions or diseases which may increase the risk of study subjects or
             interfere with the study outcome

          -  General conditions in which subjects are not suitable to participate in the study
Clinical trial NCT00303771 (phase 3, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: fluorouracil, irinotecan hydrochloride, leucovorin calcium
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the colon or rectum

               -  Metastatic disease

               -  Unresectable disease

          -  Measurable disease that is outside the field of prior irradiation

          -  No brain metastases

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 60-100%

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Transaminases ≤ 5 times normal

          -  Bilirubin ≤ 1.5 times normal

          -  Alkaline phosphatase < 3 times normal (5 times normal if due to hepatic involvement)

          -  Creatinine clearance > 45 mL/min

          -  Life expectancy > 3 months

          -  No psychological, social, or geographical situation that would preclude study
             treatment

          -  No chronic diarrhea or enteropathy

          -  No coronary insufficiency or symptomatic cardiac disease

          -  No other malignancy unless curatively treated

          -  No contraindication to chemotherapy

        PRIOR CONCURRENT THERAPY:

          -  At least 6 months since prior adjuvant chemotherapy for the primary tumor

          -  No prior extensive resection

          -  No other concurrent anticancer therapy
Clinical trial NCT00357994 (phase 3, status: completed)
Conditions: advanced parkinson's disease
ICD codes: G20
Drugs: levodopa carbidopa intestinal gel (lcig), placebo gel, levodopa carbidopa (lc) oral encapsulated immediate release (ir) tablets, placebo (pbo) oral capsules
SMILES: C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O, [H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O, C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Idiopathic Parkinson's disease (PD) according to United Kingdom Parkinson's Disease
             Society (UKPDS) Brain Bank Criteria

          -  Levodopa-responsive participants who demonstrate some identifiable 'on response,'
             established by Investigator observation

          -  Demonstrate severe motor fluctuations in spite of individually optimized treatment and
             where therapy options are indicated

        Exclusion Criteria:

          -  Diagnosis is unclear or a suspicion of other parkinsonian syndromes exists such as
             secondary parkinsonism

          -  Undergone surgery for the treatment of PD

          -  Contraindications to levodopa

          -  Subjects with any neurological deficit that may interfere with the study assessments
Clinical trial NCT01633944 (phase 3, status: completed)
Conditions: low back pain
ICD codes: M54.50, M54.51, M54.59
Drugs: buprenorphine, placebo
SMILES: NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of moderate to severe low back pain for ≥6 months

          -  Treating CLBP with a stable daily maintenance dose of non-opioid analgesic medication
             up to 10 mg morphine sulfate equivalents (MSE) per day for ≥4 weeks. (Additional as
             needed [PRN] non-opioid analgesic medications permitted on top of the stable daily
             maintenance dose of non-opioid analgesic)

          -  Stable health, as determined by Principal Investigator

          -  Are female who are practicing abstinence or using a medically acceptable form of
             contraception or have been post-menopausal, biologically sterile, or surgically
             sterile for more than 1 year

          -  Willing and able to comply with all protocol required visits and assessments

        Exclusion Criteria:

          -  Current cancer related pain or received chemotherapy with 6 months of screening

          -  Receiving opioid analgesic medication >10 mg MSE per day within 28 days of screening

          -  Subjects with a history of other chronic painful conditions

          -  Reflex sympathetic dystrophy or causalgia, acute spinal cord compression, cauda equina
             compression, acute nerve root compression, meningitis, or discitis

          -  Allergy or contraindications to any opioid or acetaminophen

          -  Surgical procedure for relief of pain with 6 months

          -  Hypokalemia or clinically unstable cardiac disease, including: unstable atrial
             fibrillation, symptomatic bradycardia, unstable congestive heart failure, or active
             myocardial ischemia

          -  QT interval corrected using Fridericia's formula (QTcF) of ≥450 milliseconds on the
             12-lead electrocardiogram (ECG)

          -  History of long QT syndrome or a family member with this condition

          -  Moderate to severe hepatic impairment

          -  Moderate to severe renal impairment

          -  Current or past history of alcohol abuse

          -  Positive urine toxicology screen for drug of abuse

          -  History or abnormalities on physical exam, vital signs, electrocardiogram, or
             laboratory values
Clinical trial NCT00373256 (phase 3, status: completed)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: sunitinib, paclitaxel, bevacizumab, paclitaxel
SMILES: CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of advanced breast cancer.

          -  Measurable disease as per RECIST (Response Evaluation Criterion) in Solid Tumors or
             bone-only disease.

          -  ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1.

        Exclusion Criteria:

          -  No prior treatment with cytotoxics in the advanced disease setting.

          -  HER2/neu positive disease unless trastuzumab was previously received or is
             contraindicated.

          -  Treatment with a taxane in the adjuvant setting unless disease free interval >12
             months after end of treatment.
Clinical trial NCT00484289 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: abatacept
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
Eligibility criteria:

        Inclusion Criteria

          -  The participants who completed the 169 days, full study period of Phase II (IM101-071)
             and were not administered other biologics between completion of IM101-071 and
             registration of this long-term study.

          -  The participants of the Phase I study (IM101-034), who received abatacept, except
             participants who were withdrawn from the study due to safety problems related to
             abatacept.

          -  New subjects with MTX intolerance: rheumatoid arthritis (RA) patients to whom MTX
             cannot be administered for safety reasons and who present an inadequate response to
             disease-modifying antirheumatic drugs (DMARDs;excluding MTX) or biologics (new
             subjects with MTX intolerance: RA patients who present an inadequate response to
             DMARDs).

        Exclusion Criteria

          -  Women of childbearing potential (WOCBP) who were unwilling or unable to use an
             acceptable method of contraception.

          -  Participants who have received non approved or investigational biologics (other than
             abatacept from previous or ongoing studies in Japan) at registration.

          -  Participants who have received treatment with any investigational drug within 56 days
             before registration or five half-lives (whichever is the longest).

          -  Participants currently receiving treatment with leflunomide, mycophenolate mofetil,
             calcineurine inhibitors such as cyclosporine and tacrolimus, D-Penicillamine,
             Cyclophosphamide, or immunoadsorption columns.

          -  The participants who completed Phase II (IM101-071) are not applicable in the
             following instances at time of registration: with active vasculitis, symptoms of
             severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal,
             pulmonary, cardiac, neurological, or cerebral disease, breast cancer, or a history of
             cancer within the last 5 years, evidence of active or latent bacterial , viral
             infections, any serious or chronic, at risk of tuberculosis (TB), with any
             opportunistic infections, laboratory values of hemoglobin < 8.5 g/dL, white blood
             cells (WBC) < 3,000/mm^3, Platelets < 100,000/mm^3, Serum creatinine > 2 times upper
             limit of normal (ULN), Serum alanine transaminase or aspartate aminotransferase > 2
             times ULN.
Clinical trial NCT00613457 (phase 3, status: completed)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: dexamethasone, asparaginase, asparaginase, cyclophosphamide, cytarabine, daunorubicin, doxorubicin, etoposide, ifosfamide, mercaptopurine, methotrexate, prednisone, thioguanine, vincristine, vindesine
SMILES: C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, N[C@@H](CC(O)=O)C(O)=O, N[C@@H](CC(O)=O)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O, S=C1N=CNC2=C1NC=N2, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, NC1=NC(=S)C2=C(N1)N=CN2, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, [H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@@H]5C[N@@](C[C@](O)(CC)C5)CCC5=C4NC4=CC=CC=C54)C(=O)OC)N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed acute lymphoblastic leukemia (ALL)

          -  No secondary ALL

          -  More than 4 weeks since prior chemotherapy

          -  More than 4 weeks since prior steroids

        Exclusion Criteria:

          -  Prior disease that would preclude treatment with chemotherapy
Clinical trial NCT00251095 (phase 3, status: terminated)
Conditions: breast neoplasm
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: taxol, tocosol paclitaxel
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Reason stopped: 
    failed primary endpoint
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with histologic diagnosis of breast carcinoma

          -  Stage IV (M1) disease

          -  Adult (18 years of age or older) patients

        Exclusion Criteria:

          -  Patients treated with a taxane within the past year

          -  Patients whose tumor tissue is known to show over expression of HER2/neu
Clinical trial NCT00361582 (phase 3, status: completed)
Conditions: osteoarthritis, pain assessment, arthralgia
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019, M26.621, M26.622, M26.623, M26.629
Drugs: cg5503 ir; tapentadol
SMILES: CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of chronic osteoarthritis of the hip or the knee based on clinical
             and radiographic (X-Ray) criteria defined by standard accepted guidelines

          -  candidate (qualifies) for primary one-sided total or partial joint replacement surgery
             due to noninflammatory, end-stage degenerative joint disease (arthritis)

          -  requires daily doses of analgesic medication for chronic pain.

        Exclusion Criteria:

          -  History of seizure disorder or epilepsy suggested by the presence of any of the
             following

          -  History of chronic hepatitis B and C or human immunodeficiency virus, or presence of
             active hepatitis B and C within the past 3 months before screening

          -  currently treated with anticonvulsants, monoamine oxidase inhibitors, tricyclic
             antidepressant, neuroleptics, or serotonin norepinephrine reuptake inhibitors.
Clinical trial NCT00458276 (phase 3, status: terminated)
Conditions: heart diseases, hypertension, pulmonary
ICD codes: I11.0, I11.9, I27.1, I51.9, I09.9, I27.9, I01.8, I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: tezosentan, placebo
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=NC=C(C=C2)C(C)C)N=C(N=C1OCCO)C1=CC(=NC=C1)C1=NNN=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    6 month vital status report not collected after 28 day follow up analysis indicated no
    difference between placebo & tezosentan
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients ≥ 18 years of age

          -  Male or female patients (females of child-bearing potential must have been surgically
             sterilized or use a reliable method of contraception).

          -  Patients undergoing complex* cardiac surgery on CPB and having systolic PAP > 40 mmHg
             or mean PAP > 30 mmHg (*surgery on 2 valves, 1 valve and revascularization, or
             reoperation of a valve)

          -  Patients undergoing cardiac surgery on CPB and having pre-operative pulmonary
             hypertension due to left heart disease with systolic PAP > 60 mmHg

          -  Signed written informed consent

        Exclusion Criteria:

          -  Systolic blood pressure < 100 mmHg

          -  Significant chronic lung disease

          -  Emergency surgery

          -  Pregnant/breast-feeding

          -  Investigational drug use within 28 days prior to randomization

          -  Complex adult congenital heart disease.

          -  Severe concomitant illness limiting life expectancy to < 6 months

          -  Participation in a device study that will affect the outcome of the study

          -  Pre-operative use of balloon pump, inotropes/vasopressors, treatment of pulmonary
             arterial hypertension

          -  Known hypersensitivity to tezosentan or drugs of the same class, or any of their
             excipients

          -  Severe liver impairment